VivoSim Labs (VIVS) director David Gobel receives 15,000 restricted stock units

Rhea-AI Filing Summary

VivoSim Labs director David Gobel received 15,000 shares of common stock in the form of restricted stock units at no cost on January 27, 2026. These units will vest on the earlier of January 27, 2027 or the company’s next annual stockholder meeting, with potential acceleration if there is a change of control. After this award, Gobel beneficially owns 15,000 shares directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gobel David

(Last) (First) (Middle)

11555 SORRENTO VALLEY ROAD

SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VivoSim Labs, INC. [ VIVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/27/2026		A		15,000(1)	A	$0.00	15,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Norman Staskey, attorney-in-fact	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did VivoSim Labs (VIVS) report for David Gobel?

VivoSim Labs reported that director David Gobel received 15,000 shares of common stock in the form of restricted stock units on January 27, 2026. The units were granted at a price of $0.00 per share as equity compensation.

How many VivoSim Labs (VIVS) shares does David Gobel now beneficially own?

After the reported transaction, director David Gobel beneficially owns 15,000 shares of VivoSim Labs common stock. All of these shares are tied to restricted stock units reported as directly owned, reflecting his current equity stake from this grant.

When do David Gobel’s VivoSim Labs (VIVS) restricted stock units vest?

The 15,000 restricted stock units granted to David Gobel vest on the earlier of January 27, 2027 or the date of VivoSim Labs’ next annual stockholder meeting. This vesting schedule aligns his compensation with ongoing board service.

What type of equity award did VivoSim Labs (VIVS) grant to David Gobel?

VivoSim Labs granted David Gobel restricted stock units (RSUs) representing 15,000 shares of common stock. RSUs are a form of stock-based compensation that convert into shares upon vesting, subject to continued service and specified conditions.

Is David Gobel’s VivoSim Labs (VIVS) equity award affected by a change of control?

Yes. The filing states that the 15,000 restricted stock units granted to David Gobel are subject to acceleration in the event of a change of control of VivoSim Labs. This means vesting may occur sooner if such a transaction happens.

What is David Gobel’s role at VivoSim Labs (VIVS) related to this stock grant?

David Gobel is identified as a director of VivoSim Labs. The 15,000-share restricted stock unit grant reported represents equity compensation tied to his board role, aligning his interests with those of the company’s stockholders.